Eli Lilly and Company (LLY) on Decifer

Decifer ranks LLY number 98 of 268 tracked names on durable business quality.

Why it ranks here

• Sales are growing about 45% a year, faster than 87 in 100 companies we measure.
• It keeps about 14 cents of every sales dollar as cash, safer than 74 in 100 companies we measure.
• It earns about 28% a year on the money put into the business, better than 93 in 100 companies we measure.
• It costs about 43 times its yearly profit; the middle of its industry is 42. Cheaper than 45 in 100 companies we measure, against their own industries.

The current read

The evidence on LLY lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• GLP-1 & Metabolic Disease Wave: GLP-1 receptor agonists have demonstrated large-scale efficacy in obesity and diabetes, triggering a multi-hundred-billion-dollar demand and capex surge across pharma and diabetes-device makers.

Read the full LLY research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.